Portfolio company
Remepy
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
Remepy develops hybrid drugs combining prescription medicines with personalized therapeutic software for pharmaceutical companies and patients with neurological or immunological conditions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Closed Loop Medicine
This company develops software-drug combination products to provide personalised dosing and digital therapy for patients with chronic conditions and their clinicians.
RebrAIn
The company develops artificial intelligence software to help neurosurgeons identify optimal brain targets for deep brain stimulation and lesioning treatments.
MindAhead
This company develops a digital therapy application for individuals with mild cognitive impairment and dementia to slow cognitive decline.
MeOmics
The company develops a precision psychiatry platform using patient-derived stem cells and AI to help drug developers accelerate psychiatric medicine discovery.
NeuraLight
The company develops an artificial intelligence platform measuring eye movements to create digital biomarkers for pharmaceutical companies and researchers treating neurological disorders.
CellRep
CellRep develops an artificial intelligence platform discovering small molecules that rejuvenate immune cells for developers of cell therapies and regenerative medicine.
DEEP Measures
This company provides a platform for developing and validating digital biomarkers and endpoints for pharmaceutical companies and clinical research organisations.
Linari Medical
This company develops telemedicine devices for neuro-visual and cognitive rehabilitation in patients with visual field defects and brain injuries.
